Biotech Value Stocks Climb Out of Their Sick Bed

📆 03.11.2019 6:30:00
📰 WSJ

⏱ Reading Time:
17 sec. here
2 min. at publisher
📊 Quality Score:
News: 10%
Publisher: 63%

Россия Новости Новости

Россия Последние новости,Россия Последние новости

Heard on the Street: Recent good news from Biogen and Bristol-Myers Squibb bolsters hope that years of weak performance may be ending

The biotechnology universe is divided into two groups.

The majority are companies without profits, or even sales, chasing a scientific breakthrough and the resulting massive payoff for investors. A much smaller group of companies have graduated to megacap status. Like most companies of their size, these sport massive profits and cash flows, with much less growth potential.

Написать комментарий

No, you are correct🧡

I guess that could happen))😀

Мы обобщили эту новость, чтобы вы могли ее быстро прочитать.Если новость вам интересна, вы можете прочитать полный текст здесь Прочитайте больше:

Россия Последние новости, Россия Последние новости

Similar News:Вы также можете прочитать подобные новости, которые мы собрали из других источников новостей

Berkshire Hathaway’s Quarterly Earnings Fell as Unrealized Investment Gains DeclinedWarren Buffett’s Berkshire Hathaway said third-quarter earnings fell as unrealized investment gains declined but operating earnings climbed In other words...he made money. Bail! There are plenty of other choices. It's a pity, but no better idea.
Источник: WSJ - 🏆 98. / 63 Прочитайте больше »